WO2014067281A1 - 盐酸他喷他多晶型c及其制备方法和应用 - Google Patents
盐酸他喷他多晶型c及其制备方法和应用 Download PDFInfo
- Publication number
- WO2014067281A1 WO2014067281A1 PCT/CN2013/075585 CN2013075585W WO2014067281A1 WO 2014067281 A1 WO2014067281 A1 WO 2014067281A1 CN 2013075585 W CN2013075585 W CN 2013075585W WO 2014067281 A1 WO2014067281 A1 WO 2014067281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloride
- preparation
- hydrochloride polymorph
- tapentadol
- tapentadol hydrochloride
- Prior art date
Links
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 title claims abstract description 32
- 229960004143 tapentadol hydrochloride Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 40
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 238000000862 absorption spectrum Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 4
- 206010046543 Urinary incontinence Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 238000004566 IR spectroscopy Methods 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 229940008309 acetone / ethanol Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011265 semifinished product Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960005126 tapentadol Drugs 0.000 description 3
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
- 229950000178 cyclopentobarbital Drugs 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZXRCAYWYTOIRQS-UHFFFAOYSA-N hydron;phenol;chloride Chemical compound Cl.OC1=CC=CC=C1 ZXRCAYWYTOIRQS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention belongs to the technical field of medicine, and particularly relates to a crystalline form C of tapentadol hydrochloride and a preparation method and application thereof. Background technique
- Tapentadol Hydrochloride is the salt of tapentadol, the chemical name 3-[(lR,2R)-3-(dimethylamino)ethylidene-2-methylpropyl] Phenol hydrochloride, English name: 3-[(lR,2R)-3-(Dimethylamino)-l-ethyl-2-methylpropyl]phenol hydrochloride , Molecular formula: C 14 H 23 NOHCl, its structural formula is as follows:
- Tapentadol Hydrochloride is a new central analgesic with dual action mechanism developed by Johnson & Johnson.
- Tapentadol hydrochloride is a novel strong central analgesic with both opioid receptor (MOR) agonism and norepinephrine (NE) reabsorption inhibition (TzschentkeTM, et al ., J. Pharm. Exper. Therap., 2007, 323, 265).
- MOR opioid receptor
- NE norepinephrine
- Tapentadol hydrochloride is a novel strong central analgesic with both opioid receptor (MOR) agonism and norepinephrine (NE) reabsorption inhibition (TzschentkeTM, et al ., J. Pharm. Exper. Therap., 2007, 323, 265).
- FDA US Food and Drug Administration
- the Chinese patent publication CN 1997621 B discloses two crystal forms of tapentadol hydrochloride: Form A and Form B. Dissolve tapentadol hydrochloride with acetone or acetonitrile as solvent, or use slow evaporation method, or store at -40 °C for 72 hours to obtain crystal form A. After crystal form A is ground at low temperature for 15 minutes, 125 ° in an oven. Form B was maintained for 30 minutes to obtain Form B. Summary of the invention
- the present invention provides a crystalline form C of tapentadol hydrochloride, a method for preparing the same, and a crystal form of tapentadol hydrochloride for use in the preparation of a pharmaceutical composition.
- a crystalline form C of tapentadol hydrochloride, the X-ray powder diffraction expressed in terms of 2 ⁇ angle has the following diffraction peaks:
- the X-ray powder diffraction was measured using Cu ⁇ radiation.
- the powder X-ray diffraction pattern of the cyclopental hydrochloride C is shown in Fig. 1.
- the palladium polymorphic hydrazine hydrochloride was prepared under the same test conditions.
- the powder X-ray diffraction data were obtained, wherein the strong diffraction peaks of the crystalline form were: 14.624 (92.5%), 16.713 (25.4%), 18.999 (36.1%), 20.460 (100.0%), 21.782 (31.4%), 25.123 (29.4%), 25.920 (35.6%), 26.209 (42.5%), 27.388 (45.1%), 27.774 (22.8%) and 28.854 (18.4%); and the crystalline form C obtained by the present invention
- the strong diffraction peaks were 14.627 (100%), 15.476 (20.7%), 16.710 (33.7%), 18.999 (48.3%), 20.479 (80.7%), 21.790 (27.9%), 25.110 (35.2%), 25.911 ( 36.4%), 26.292 (58.5%), 27.385 (32.8%) and 27.775 (37.5%), the diffraction peaks of the two have significant differences, and it can be seen that Form A and Form C are different.
- the powdered X-ray diffraction data was prepared under the same test conditions according to the Chinese patent method of CN 1077566 C.
- the strong diffraction peak of crystal form B was: 14.574 (100%), 15.416 (20.7%), 17.769 (26.5%), 18.013 (60.3%), 19.615 (39.6%), 20.188 (24.4%), 21.984 (63.8%), 24.730 (43.9%), 27.757 ( 22.9%), 28.189 (37.4%), 31.141 (22.6%), the diffraction peak is significantly different from the above crystal form C, and it can be seen that the crystal form B is different from the crystal form C.
- the melting range of the polyhedral hydrochloride C is: 201 ⁇ 204 ° C, and the characteristic peaks of the infrared absorption spectrum are: 3236 cm 1 and 3168 cm _1 (double peak), 2961 cm 1 , 2703 cm 1 , 1217 cm 1 , 877 cm — 1 and 710cm—
- the invention also provides a preparation method of pitazone hydrochloride polymorph C, the operation is as follows: adding a mixed solvent of ethanol and acetone to the crude peptacoxib hydrochloride, heating to 60-70 V to completely dissolve, controlling The cooling rate was slowly cooled to 15 to 25 ° C, and the solid was precipitated, and the solid was precipitated to obtain the above-mentioned polymorphic form C.
- the crude dasteendramine hydrochloride generally refers to various amorphous forms of tapentadol hydrochloride in the prior art, and may also be various crystalline forms of tapentadol hydrochloride or a mixture thereof in a crystalline state;
- the crude product of tapentadol hydrochloride is commercially available, and can also be synthesized according to prior art methods, such as the synthetic methods disclosed in the patent document methods of US 6,248,737, US 6,344,558 and CN 102,557,851 A.
- the above-described crude product of tapentadol is obtained by the above method, and the polymorphic form C of the spray of the present invention can be obtained.
- composition and ratio of the mixed solvent have a great influence on the yield and purity of the obtained polyhedral hydrochloride C (which is likely to cause mixed crystals), and the volume ratio of ethanol to acetone in the mixed solvent. It is preferably 1: 2 to 10.
- the concentration of tapentadol hydrochloride mainly affects the yield of the polymorphic form C of the spray, which is preferably 10 g: 20 to 150 mL.
- the cooling rate is critical to the precipitation of the crystal, and the hydrochloric acid is
- the purity of the sprayed polymorph C has an effect, and the cooling rate is preferably 1 to 5 ° C / min.
- the heat retention time is preferably from 1 to 5 hours, and in the time range, the polymorphic form C of the spray is higher in yield and the crystal form is relatively simple.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of said cata spray form C as an active ingredient together with one or more pharmaceutically acceptable inert non-toxic carriers.
- the inert non-toxic carrier can be selected according to the knowledge already available to those skilled in the art, including pharmaceutically acceptable diluents, flavoring agents, solubilizers, lubricants, and encapsulating agents, such as magnesium phosphate, slip powder sugar, and lactose. , pectin, starch and gelatin.
- the crystalline form C of tapentadol hydrochloride in the present invention can be applied to the preparation of a medicament for treating pain or urinary incontinence.
- the sprayed polymorph C is stable in the surrounding environment and can be used for preparing a pharmaceutical composition; within the range of process parameters described in the preparation method, multiple batches are repeated, Very good current.
- Fig. 1 is an XRPD diagram of the polymorphic form C of T. catarrhalis prepared in Example 1, in which the abscissa is the diffraction angle and the ordinate is the diffraction intensity;
- Example 2 is an infrared spectrum diagram of the polymorphic form C of T. catarrhalis prepared in Example 1, in which the abscissa is the wavelength and the ordinate is the light transmittance;
- Fig. 3 is a DSC chart of the polymorph C of hydrochloric acid prepared in Example 1, in which the yaw is the temperature and the ordinate is the heat flow value to the sample.
- tapropion hydrochloride polymorph A The preparation method of tapropion hydrochloride polymorph A is the same as the preparation method of the embodiment 4 of Chinese patent application CN 1997621 A, 350 mg of tazodazine hydrochloride is dissolved in 50 ml of acetonitrile, and the mixture is heated again to 37 ° C. Stir in a water bath for 1.5 h. Any insoluble residue was removed by filtration. 35 ml of the clear solution was removed on a rotary evaporator at 70-80 mbar and 30 ° C water bath temperature.
- Form B of tapentadol hydrochloride was prepared according to Chinese Patent Example No. 24 of the publication No. CN 1077566 C, and the obtained product was characterized by X-ray powder diffraction analysis, DSC and infrared spectroscopy.
- Example 6 X-ray powder diffraction spectrum of Form A, Form B and Form C:
- Measuring instrument X'Pert PRO diffractometer, PHILIPS
- Figure 1 is an X-ray diffraction pattern of Form C obtained in Example 1.
- the X-ray diffraction measurement data of different crystal forms are shown in Table 1.
- the instrument used was Nicolet 8700, Thermo Scientific Instrument Co. USA, and the scanning range was ⁇ O ⁇ 00 cm -1 .
- the determination method was as follows: Take the appropriate amount of sample, refer to the relevant requirements of Appendix IVC of the Chinese Pharmacopoeia 2010, and use potassium bromide tablet to determine The infrared spectrum of the sample. 2 is an infrared spectrum diagram of Form C obtained in Example 1. Infrared absorption spectrum characteristics of different crystal forms The peaks are listed in Table 2.
- FIG. 3 is the DSC chart of the crystal form C obtained in Example 1. The DSC measurement results for the different crystal forms are shown in Table 3.
- Example 9-11 Preparation of tapentadol hydrochloride tablets:
- Component dosage component dosage component dosage hydrochloric acid catarrhal polymorph C C8.22 g hydrochloric acid polypentasyl C 87.4g hydrochloric acid polypentasyl C 6.5g Cross-linked povidone 25g Carboxymethyl starch sodium 25g Cross-linked povidone 25g Microcrystalline cellulose 100g Low-substituted hydroxypropyl cellulose 10g Carboxymethyl starch sodium 25g Low-substituted hydroxypropyl cellulose 10g Microcrystalline cellulose 90g Lactose 7g
- the raw materials and materials received were crushed separately and passed through a 80 mesh sieve for use.
- the thickness should not exceed 2.5cm, dry at 50 ⁇ 60 °C for 2 hours, every 30 minutes during the drying process, flip once, the moisture is controlled at 1% ⁇ 3 % is appropriate.
- the dried granules are added to the prescribed amount of magnesium stearate, and the lubricant and dry granules are uniformly mixed using mechanical mixing or manual mixing.
- the total mixed dry granules are sifted with a 24 mesh sieve to obtain a half-mouth.
- the weight of the tablets adjust the weight of the tablets, control the hardness of the tablets in 5 ⁇ 6kg, and compress.
- the resulting tablets can be used to treat pain or urinary incontinence.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种盐酸他喷他多晶型C,其用衍射角2θ表示的粉末X射线衍射图中显示的特征峰为14.627(100%)、15.476(20.7%)、16.710 (33.7%)、18.999(48.3%)、20.479(80.7%)、21.790(27.9%)、25.110 (35.2%)、25.911(36.4%)、26.292(58.5%)、27.385(32.8%)和27.77 (37.5%),该晶型稳定性好,本发明还提供了该晶型的制备方法及其应用,使用该方法制备盐酸他喷他多晶型具有重复性高,操作性强的特点,可用于制备药物组合物,在制备治疗疼痛或尿失禁的药物中具有重要的应用意义。
Description
说 明 书
盐酸他喷他多晶型 C及其制备方法和应用 技术领域
本发明属于医药技术领域,具体涉及盐酸他喷他多的晶型 C及其制备 方法和应用。 背景技术
盐酸他喷他多 (Tapentadol Hydrochloride )是他喷他多的盐酸盐, 化 学名为 3-[(lR,2R)-3- (二甲胺基)小乙基 -2-甲基丙基]苯酚盐酸盐, 英文名: 3-[(lR,2R)-3-(Dimethylamino)-l-ethyl-2-methylpropyl]phenol hydrochloride , 分子式: C14H23NOHCl, 其结构式如下:
CH3
Tapentadol Hydrochloride 是由美国 Johnson & Johnson公司研发的一种具有双重作用机制的新 型中枢型镇痛药。
盐酸他喷他多 (Tapentadol )是一种新型兼有 μ阿片受体( MOR )激 动和去甲肾上腺素( Norepinephrine,NE )重吸收抑制双重作用方式的强中 枢镇痛药(Tzschentke TM, et al., J.Pharm.Exper. Therap., 2007, 323, 265)。 2008年 1月 23日, 美国食品与药品管理局 (FDA ) 已经接受盐酸他喷他 多即释片的新药上市申请, 2008年 11月 21 日由美国 FDA批准上市, 临 床上用于解除成人中枢神经系统的中重度急性疼痛的治疗。 研究结果显 示, 他喷他多不依赖代谢活化, 没有活性代谢产物, 对急性、 炎性和慢性 神经病理性疼痛模型都有良好效果, 其效能介于吗啡(Morphine )和曲马 多 ( Tramadol )之间, 静脉注射或口服均能获得满意的血药浓度, 且比吗 啡更不易产生镇痛耐受和躯体依赖, 并比等效镇痛剂量的强阿片类药物更
能改善副作用 (尤其是胃肠副作用如恶心和呕吐), 可望在急性和慢性中 至重度疼痛治疗中前景更好。
公告号为 CN 1997621 B的中国专利公开了盐酸他喷他多的两种晶 型: 晶型 A和晶型 B。 以丙酮或者乙腈作为溶剂溶解盐酸他喷他多, 采用 緩慢蒸发的方法, 或者在 -40 °C存放 72小时得到晶型 A, 将晶型 A在低温 时研磨 15分钟后, 在烘箱中 125 °C保持 30分钟可得到晶型 B。 发明内容
本发明提供了一种盐酸他喷他多的晶型 C及其制备方法及应用,该盐 酸他喷他多的晶型可用于制备药物组合物。
一种盐酸他喷他多的晶型 C , 以 2Θ角度表示的 X-射线粉末衍射具有 如下衍射峰:
所述的 X-射线粉末衍射采用 Cu Κα放射线进行测量。
所述的盐酸他喷他多晶型 C的粉末 X射线衍射图如图 1所示, 按照公 告号为 CN 1997621 Β中国专利的方法制备了盐酸他喷他多晶型 Α, 在相 同的测试条件下得到了其粉末 X射线衍射数据, 其中, 晶型 Α较强的衍 射峰为: 14.624( 92.5% )、 16.713( 25.4% )、 18.999( 36.1 % )、 20.460( 100.0% )、
21.782 (31.4%), 25.123 (29.4%)、 25.920 (35.6%), 26.209 (42.5%)、 27.388 ( 45.1% )、 27.774 ( 22.8% )和 28.854 ( 18.4% ); 而本发明得到的晶 型 C较强的衍射峰为 14.627 ( 100% )、 15.476 ( 20.7% )、 16.710 ( 33.7% )、 18.999 (48.3%)、 20.479 ( 80.7%)、 21.790 (27.9%)、 25.110 ( 35.2%)、 25.911 (36.4%)、 26.292 (58.5%)、 27.385 (32.8%)和 27.775 (37.5%), 两者的衍射峰有着明显差别, 可见晶型 A和晶型 C不同。
按照公告号为 CN 1077566 C的中国专利的方法制备了盐酸他喷他多 晶型 B , 在相同的测试条件下得到了其粉末 X射线衍射数据, 其中, 晶型 B较强的衍射峰为: 14.574 ( 100% ), 15.416 (20.7%), 17.769 ( 26.5% ), 18.013 (60.3%)、 19.615 (39.6%)、 20.188 (24.4%), 21.984 ( 63.8%)、 24.730 (43.9%)、 27.757 (22.9% ), 28.189 (37.4%), 31.141 (22.6%), 该衍射峰与上述晶型 C有着明显差别, 可见晶型 B与晶型 C不同。
所述的盐酸他喷他多晶型 C的熔程为: 201~204°C, 红外吸收光谱特征 峰为: 3236 cm1和 3168cm_1(双峰)、 2961cm1、 2703cm1、 1217cm1、 877cm— 1 和 710cm—
本发明还提供了一种盐酸他喷他多晶型 C的制备方法, 操作如下: 向 盐酸他喷他多粗品中加入乙醇和丙酮的混合溶剂, 加热至 60~70 V使其完 全溶解, 控制降温速度令其緩慢冷却至 15~25°C, 保温, 析出固体, 过滤, 得到所述的盐酸他喷他多晶型 C。
所述的盐酸他喷他多粗品泛指现有技术中各种非结晶状态的盐酸他 喷他多, 也可以是结晶状态的盐酸他喷他多的各种晶型或其混合; 所述的 盐酸他喷他多粗品可以市购, 也可以根据现有技术方法合成, 例如 US 6248737、 US6344558以及 CN 102557851 A的专利文献方法中所公开的 合成方法。 所述的盐酸他喷他多粗品在通过上述方法, 可以得到本发明所 述的盐酸他喷他多晶型 C。
所述的混合溶剂的成分和比例对得到的盐酸他喷他多晶型 C的产率和 纯度(否则容易产生混晶)有着较大的影响, 所述的混合溶剂中乙醇和丙 酮的体积比优选为 1: 2~10。
盐酸他喷他多的浓度主要影响所述盐酸他喷他多晶型 C的产率, 所述 盐酸他喷他多和混合溶剂的用量比优选为 10g: 20~150mL。
本发明中, 所述的降温速度对晶体的析出比较关键, 会对所述盐酸他
喷他多晶型 C的纯度产生影响, 所述的降温速度优选为 l~5°C/min。
本发明中, 所述的保温的时间优选为 l~5h, 在此时间范围内, 所述 盐酸他喷他多晶型 C产率较高, 晶型较单一。
本发明还提供了一种药物组合物, 包括治疗有效量的所述的盐酸他喷 他多晶型 C作为活性成分以及一种或多种可药用的惰性无毒载体。 所述的 惰性无毒载体可以根据本领域技术人员已有的知识进行选择, 包括药学上 所用的稀释剂、 香味剂、 增溶剂、 润滑剂以及包裹剂等, 例如磷酸镁、 滑 粉糖、 乳糖、 果胶、 淀粉和明胶等。
本发明中的盐酸他喷他多的晶型 C可以应用于制备治疗疼痛或尿失禁 的药物。
同现有技术相比, 该盐酸他喷他多晶型 C在周围环境中很稳定, 可以 用于制备药物组合物; 在该制备方法所述的工艺参数范围内, 重复多个批 次, 重现性极好。 附图说明
图 1为实施例 1制得的盐酸他喷他多晶型 C的 XRPD图, 图中, 横 坐标为衍射角, 纵坐标为衍射强度;
图 2为实施例 1制得的盐酸他喷他多晶型 C的红外光谱图, 图中,横 坐标为波长, 纵坐标为透光率;
图 3为实施例 1制得的盐酸他喷他多晶型 C的 DSC图, 图中, 横坐 标为温度, 纵坐标为流向样品的热流数值。 具体实施方式 实施例 1盐酸他喷他多晶型 C的制备:
将盐酸他喷他多粗品 10g加入 80mL丙酮 /乙醇( 6:1 )中,加热到 60 °C 溶解, 以 5 °C/min的温度进行降温, 降至 20°C时, 保温 3h, 析晶, 过滤, 滤饼 80 ~ 90 °C真空干燥 24小时得到盐酸他喷他多晶型 C, 为白色颗粒状 晶体, 重量为 9.0g, 收率: 90.0%。 所得产品通过 X-射线粉末衍射、 DSC 和红外光谱分析表征。
实施例 2盐酸他喷他多晶型 C的制备:
将盐酸他喷他多粗品 10g加入 40mL丙酮 /乙醇(4:1 ) 60 °C加热溶解, 以 5°C/min的温度, 进行降温, 降至 20°C时, 保温 3h, 析晶, 过滤, 滤 饼 80 ~ 90°C真空干燥 24小时得到盐酸他喷他多晶型 C, 为白色颗粒状晶 体, 重量为 8.7g, 收率: 87.0%。 所得产品通过 X-射线粉末衍射、 DSC和 红外光谱分析表征。 实施例 3盐酸他喷他多晶型 C的制备:
将盐酸他喷他多粗品 10g加入 lOOmL丙酮 /乙醇(6:1 ) 60 °C加热溶解, 以 5°C/min的温度, 进行降温, 降至 20°C时, 保温 3h, 析晶, 过滤, 滤 饼 80 ~ 90°C真空干燥 24小时得到盐酸他喷他多晶型 C, 为白色颗粒状晶 体, 重量为 8.5g, 收率: 85.0%。 所得产品通过 X-射线粉末衍射、 DSC和 红外光谱分析表征。 实施例 4盐酸他喷他多晶型 A的制备:
盐酸他喷他多晶型 A的制备方法与中国专利申请 CN 1997621 A中实 施例 4的制备方法相同, 将 350mg的盐酸他喷他多溶于 50ml乙腈, 将该 混合物再加热到 37°C的水浴中搅拌 1.5h。 通过过滤去除任何不溶性残余 物。 在 70-80 mbar和 30°C水浴温度下的旋转蒸发器上去除所述透明溶液 35ml。通过抽真空过滤所沉淀的固体化合物,生成盐酸他喷他多的晶型 A, 为无色菱柱状结晶, 所得产品通过 X-射线粉末衍射、 DSC和红外光谱分 析表征。 实施例 5盐酸他喷他多晶型 B的制备:
根据公告号为 CN 1077566 C的中国专利实施例 24制备得到盐酸他喷 他多的晶型 B , 所得产品其通过 X-射线粉末衍射分析、 DSC和红外光谱 分析表征。 实施例 6晶型 A、 晶型 B和晶型 C的 X-射线粉末衍射光谱:
测定仪器: X'Pert PRO型衍射仪, PHILIPS
测定 :
扫描方式:: 连续扫描 驱动方式: 0-2Θ联动
起始角度: : 0° 终止角度: 60°
扫描速度: : 0.02 秒 采样时间: 1秒
靶 材: : Cu 波 长值: 1.54056
管 电 压: : 40kV 管 电 流: 200mA
单 色 器: : 无 发散狭缝: 1度
图 1为实施例 1制得的晶型 C的 X-射线衍射图。 不同晶型的 X-衍射 测定数据列于表 1。
盐酸他喷他多不同晶型的 X-衍射测定数据
由上述实验分析数据表明: 晶型 C与晶型 A和 B都不同。 实施例 7晶型 A、 晶型 B和晶型 C的红外光谱分析:
所用仪器为 Nicolet 8700, Thermo Scientific Instrument Co. U.S.A,扫描 范围为 ^O ^OOcm—1, 测定方法如下: 取样品适量, 参照中国药典 2010 年版附录 IVC的有关要求, 采用溴化钾压片, 测定样品的红外光谱。 图 2 为实施例 1得到的晶型 C的红外光谱图。不同晶型的红外吸收光谱特征吸
收峰列于表 2。
表 2 盐酸他喷他多不同晶型的红外吸收光谱特征吸收峰 样品名称 吸收特征峰 ( cm
晶型 A 3236 cm-1 (单峰)、 2960cm- 2707cm"\ 1216cm"1 、 878cm—1 、 709cm—1 晶型 B 3225 cm-1和 3113 cm- 双峰)、 2961cm"1 > 2682cm \ 1217cm— 877cm" 711cm-1 晶型 C 3236 cm—1和 3168cm— 1 (双峰)、 2961cm"1 > 2703cm" \ 1217cm- ] '、 877cm"1 -、 710cm—1 由盐酸他喷他多不同晶型的红外吸收光谱中可以看出: 晶型 C酚羟基 的特征吸收在 3236cm—1和 3168cm"1附近以双峰形式出现, 而晶型 A只在 3236cm"1以单峰形式出现, 晶型 B在 3225 cm"1和 3113 cm"1附近以双峰形 式出现; 晶型 C的铵盐的特征吸收在 2703cm4 , 而晶型 A和晶型 B铵盐的 特征吸收分别在 2707cm—1和 2682cm-1处。 晶型 C与晶型 A或 B有着明显 的区别。 实施例 8晶型 A、 晶型 B和晶型 C的差热分析:
所用仪器为岛津 DTG-60H热重-差热分析仪, 环境气体为氮气, 升温 速度为 10.00 °C/min, 灵敏度为 0.2uw, 图 3为实施例 1得到的晶型 C的 DSC图。 不同晶型的 DSC测定结果列于表 3。
从上述测定结果可知, 实施例 1、 实施例 4和实施例 5的产物的 DSC 图在 50°C以上都只有单一的吸收峰, 说明产物都为单一晶型而不是混晶。 晶型 A或 B的克分子熔化热高于晶型 C, 晶型 C与晶型 A或 B有着明显 的区别。 实施例 9~11 盐酸他喷他多片剂的制备:
采用本发明中的盐酸他喷他多晶型 C作为活性成分,按表 4的处方制 备成盐酸他喷他多片剂 1000片。
表 1 实施例 9~11的处方
实施例 9 实施例 10 实施例 11
组分 用量 组分 用量 组分 用量 盐酸他喷他多晶型 C 58.2g 盐酸他喷他多晶型 C 87.4g 盐酸他喷他多晶型 C H6.5g
交联聚维酮 25g 羧曱基淀粉钠 25g 交联聚维酮 25g 微晶纤维素 100g 低取代羟丙纤维素 10g 羧曱基淀粉钠 25g 低取代羟丙纤维素 10g 微晶纤维素 90g 乳糖 7g
5%PVP QS 5%PVP QS 5%PVP QS 硬脂酸镁 ig 硬脂酸镁 ig 硬脂酸镁 ig
对领取的原辅料, 分别粉碎, 过 80目筛, 备用。
(1)称量与混合
根据处方, 称取原辅料, 分别放入混合搅拌器中, 混合 30min,中间停 两次, 每次把搅拌机中死角部位的药物翻动一下, 以利混合均匀。
( 2 )制备软材和颗粒
取混合均匀的粉末, 以 3%的聚乙烯吡咯烷酮为粘合剂, 搅拌均匀, 制软材, 将制得的软材, 通过 30目薛即制得所需的颗粒。
(3)湿颗粒的干燥
将制得的湿颗粒,放在烘盘内的絹布上,厚度不宜超过 2.5cm,以 50 ~ 60°C干燥 2小时, 干燥过程中每隔 30分钟, 翻动一次, 水分控制在 1%~ 3%为宜。
(4)整粒与总混
将干燥好的颗粒,加入处方量的硬脂酸镁,使用机械混合或手工掺拌, 使润滑剂和干颗粒混合均匀。 将总混后的干颗粒用 24目筛整粒, 得半成 口
(5)半成品含量测定
取半成品, 检查含量 。
(6)压片
按测得的半成品含量, 调节片重, 控制片剂的硬度在 5~6kg, 压片。 所得到的片剂可以用于治疗疼痛或尿失禁。
Claims
1、 一种盐酸他喷他多晶型 C, 其特征在于, 以 2Θ角度表示的 X-射线 粉末衍射具有如下衍射峰:
所述的 X-射线粉末衍射采用 Cu Κα放射线进行测量。
2、 根据权利要求 1所述的盐酸他喷他多晶型 C, 其特征在于, 熔程 为: 201~204°C , 红外吸收光谱特征峰为: 3236 cm4、 3168cm"1 , 2961cm— 2703cm4、 1217cm"\ 877cm 1和 710cm— ^
3、 一种如权利要求 1所述的盐酸他喷他多晶型 C的制备方法, 其特 征在于, 向盐酸他喷他多粗品中加入乙醇和丙酮的混合溶剂, 加热至 60~70°C使其完全溶解, 控制降温速度令其緩慢冷却至 15~25 °C , 保温, 析出固体, 过滤, 得到所述的盐酸他喷他多晶型 C。
4、根据权利要求 3所述的盐酸他喷他多晶型 C的制备方法, 其特征在 于, 所述的混合溶剂中乙醇和丙酮的体积比为 1 : 2~10。
5、 根据权利要求 3或 4所述的盐酸他喷他多晶型 C的制备方法, 其 特征在于,所述盐酸他喷他多粗品和混合溶剂的用量比为 10g: 20~150mL。
6、根据权利要求 3所述的盐酸他喷他多晶型 C的制备方法, 其特征在
于, 所述的降温速度为 l~5°C/min。
7、根据权利要求 3所述的盐酸他喷他多晶型 C的制备方法, 其特征在 于, 所述的保温的时间为 l~5h。
8、一种药物组合物, 其特征在于, 包括治疗有效量的如权利要求 1~2 任一项所述的盐酸他喷他多晶型 C作为活性成分以及一种或多种可药用的 惰性无毒载体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012104259497A CN102924303B (zh) | 2012-10-31 | 2012-10-31 | 盐酸他喷他多晶型c及其制备方法和应用 |
CN201210425949.7 | 2012-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014067281A1 true WO2014067281A1 (zh) | 2014-05-08 |
Family
ID=47639266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/075585 WO2014067281A1 (zh) | 2012-10-31 | 2013-05-14 | 盐酸他喷他多晶型c及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102924303B (zh) |
WO (1) | WO2014067281A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102924303B (zh) * | 2012-10-31 | 2013-11-20 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1997621A (zh) * | 2004-06-28 | 2007-07-11 | 格吕伦塔尔有限公司 | (-)-(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基丙基)-苯酚盐酸盐的晶形 |
CN101495446A (zh) * | 2006-07-24 | 2009-07-29 | 格吕伦塔尔有限公司 | 3-[(1r,2r)-3-(二甲氨基)-1-乙基-2-甲基丙基]苯酚的制备 |
CN101495445A (zh) * | 2006-07-24 | 2009-07-29 | 格吕伦塔尔有限公司 | (1r,2r)-3-(3-二甲胺基-1-乙基-2-甲基丙基)苯酚的制备方法 |
WO2011067714A1 (en) * | 2009-12-01 | 2011-06-09 | Archimica Srl | New process for the preparation of tapentadol and intermediates thereof |
WO2011128784A2 (en) * | 2010-04-05 | 2011-10-20 | Actavis Group Ptc Ehf | Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof |
WO2012023147A1 (en) * | 2010-08-16 | 2012-02-23 | Indoco Remedies Limited | Process for the preparation of tapentadol |
WO2012038974A1 (en) * | 2010-09-20 | 2012-03-29 | Ind-Swift Laboratories Limited | Process for preparing l-phenyl-3-dimethylaminopropane derivative |
WO2012089181A1 (en) * | 2010-12-30 | 2012-07-05 | Zentiva, K.S. | O-substituted (2r,3r)-3-(3-hydroxyphenyl)-2-methyl-4-pentenoic acids and a method of obtaining the same |
CN102557851A (zh) * | 2011-12-13 | 2012-07-11 | 安徽省新星药物开发有限责任公司 | 一种盐酸他喷他多及其类似物的合成新方法 |
CN102924303A (zh) * | 2012-10-31 | 2013-02-13 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101972299B1 (ko) * | 2007-11-23 | 2019-08-16 | 그뤼넨탈 게엠베하 | 타펜타돌 조성물 |
-
2012
- 2012-10-31 CN CN2012104259497A patent/CN102924303B/zh active Active
-
2013
- 2013-05-14 WO PCT/CN2013/075585 patent/WO2014067281A1/zh active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1997621A (zh) * | 2004-06-28 | 2007-07-11 | 格吕伦塔尔有限公司 | (-)-(1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基丙基)-苯酚盐酸盐的晶形 |
CN101495446A (zh) * | 2006-07-24 | 2009-07-29 | 格吕伦塔尔有限公司 | 3-[(1r,2r)-3-(二甲氨基)-1-乙基-2-甲基丙基]苯酚的制备 |
CN101495445A (zh) * | 2006-07-24 | 2009-07-29 | 格吕伦塔尔有限公司 | (1r,2r)-3-(3-二甲胺基-1-乙基-2-甲基丙基)苯酚的制备方法 |
WO2011067714A1 (en) * | 2009-12-01 | 2011-06-09 | Archimica Srl | New process for the preparation of tapentadol and intermediates thereof |
WO2011128784A2 (en) * | 2010-04-05 | 2011-10-20 | Actavis Group Ptc Ehf | Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof |
WO2012023147A1 (en) * | 2010-08-16 | 2012-02-23 | Indoco Remedies Limited | Process for the preparation of tapentadol |
WO2012038974A1 (en) * | 2010-09-20 | 2012-03-29 | Ind-Swift Laboratories Limited | Process for preparing l-phenyl-3-dimethylaminopropane derivative |
WO2012089181A1 (en) * | 2010-12-30 | 2012-07-05 | Zentiva, K.S. | O-substituted (2r,3r)-3-(3-hydroxyphenyl)-2-methyl-4-pentenoic acids and a method of obtaining the same |
CN102557851A (zh) * | 2011-12-13 | 2012-07-11 | 安徽省新星药物开发有限责任公司 | 一种盐酸他喷他多及其类似物的合成新方法 |
CN102924303A (zh) * | 2012-10-31 | 2013-02-13 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102924303A (zh) | 2013-02-13 |
CN102924303B (zh) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI305148B (zh) | ||
TWI619495B (zh) | C-met調節劑醫藥組合物 | |
JP2019163337A (ja) | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 | |
TWI667026B (zh) | 雜環化合物及其用途 | |
CN110054624B (zh) | 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途 | |
US8552038B2 (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
JP2017505796A5 (zh) | ||
RU2603138C1 (ru) | Кристаллическая форма хидамида, способ ее получения и применение | |
JPH09512283A (ja) | 抗片頭痛インドール誘導体塩類 | |
TWI718104B (zh) | AHU-377結晶型游離酸、半鈣鹽、α-苯乙胺鹽及其製備方法和應用 | |
JP2019112424A (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
CN110041326B (zh) | 盐酸小檗碱与反丁烯二酸共晶物及制备方法和其组合物与用途 | |
WO2010060387A1 (zh) | 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途 | |
WO2014067281A1 (zh) | 盐酸他喷他多晶型c及其制备方法和应用 | |
WO2018106657A1 (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
CN108440456B (zh) | 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物 | |
WO2017190568A1 (zh) | 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用 | |
US8575115B2 (en) | Crystalline form I of 3,4′5-trihydroxy-stilbene-3-β-D glucoside | |
CN101619039B (zh) | 2-(4-乙基-1-哌嗪基)-4-(4-氟苯基)-5,6,7,8,9,10-六氢芳辛并[b]吡啶及其组合物 | |
WO2016127898A1 (zh) | 一种化合物的a晶型及其制备方法 | |
WO2017162116A1 (zh) | 一种dppiv抑制剂马来酸盐的多晶型及其制备方法 | |
CN103254088B (zh) | 盐酸他喷他多晶型d及其制备方法和应用 | |
CN105399725A (zh) | 曲格列汀化合物其盐、晶体、药物组合物和用途 | |
TW202413343A (zh) | 5-(2-(4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)乙基)-5-氮雜螺[2.4]-庚-7-醇之結晶、磷酸鹽及其對映體之生物活性 | |
CN101607960B (zh) | 醋茶溴索及其组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13850979 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 10/09/2015) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13850979 Country of ref document: EP Kind code of ref document: A1 |